Risk factors for progression of normal-tension glaucoma under β-blocker monotherapy

Acta Ophthalmol. 2012 Aug;90(5):e337-43. doi: 10.1111/j.1755-3768.2012.02425.x. Epub 2012 May 2.

Abstract

Purpose: To prospectively study prognostic factors for normal-tension glaucoma (NTG) under treatment with topical β-blocker.

Methods: One hundred and forty-six eyes of 146 patients with NTG with a mean untreated intraocular pressure (IOP) of 14 mmHg, mild to moderate visual field damage and mean spherical equivalent refraction of -3.5 (-8.0 to +2.0) dioptre were randomized to topical nipradilol or timolol and followed for 3 years. The Humphrey full threshold 30-2 visual field test was performed every 6 months, and optic disc photographs were obtained every 12 months. Progression was defined as visual field progression, optic disc and/or peripapillary nerve fibre layer change, and factors relating to progression were evaluated using Cox proportional hazards models.

Results: IOP decreased by 1.0 mmHg over the 3-year period, during which 35% showed progression according to the aforementioned criteria. Optic disc haemorrhage (hazard ratio [HR] 4.00, p < 0.001) and less extent of myopia (per dioptre, HR 1.15, p = 0.013) were significant risk factors. When progression was defined by visual field progression only, less extent of myopia was again a significant risk factor (HR 1.17, p = 0.038).

Conclusion: Beside optic disc haemorrhage, less extent of myopia was a risk factor for progression in the current NTG population where most patients were mildly myopic and IOP during follow-up averaged 13.2 mmHg under topical β-blocker.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Disease Progression
  • Double-Blind Method
  • Female
  • Humans
  • Intraocular Pressure / drug effects
  • Low Tension Glaucoma / diagnosis*
  • Low Tension Glaucoma / drug therapy*
  • Male
  • Middle Aged
  • Myopia / complications
  • Ophthalmic Solutions
  • Prognosis
  • Propanolamines / therapeutic use
  • Prospective Studies
  • Risk Factors
  • Timolol / therapeutic use
  • Tonometry, Ocular
  • Vision Disorders / complications
  • Visual Fields

Substances

  • Adrenergic beta-Antagonists
  • Ophthalmic Solutions
  • Propanolamines
  • Timolol
  • nipradilol